DK1001956T3 - 2,3-Benzodiazepinderivater - Google Patents

2,3-Benzodiazepinderivater

Info

Publication number
DK1001956T3
DK1001956T3 DK98936578T DK98936578T DK1001956T3 DK 1001956 T3 DK1001956 T3 DK 1001956T3 DK 98936578 T DK98936578 T DK 98936578T DK 98936578 T DK98936578 T DK 98936578T DK 1001956 T3 DK1001956 T3 DK 1001956T3
Authority
DK
Denmark
Prior art keywords
benzodiazepine derivatives
benzodiazepines
epilepsy
stereoisomers
variables
Prior art date
Application number
DK98936578T
Other languages
Danish (da)
English (en)
Inventor
Pal Berzsenyi
Imre Moravcsik
Istvan Pallagi
Gizella Abraham
Emese Csuzdi
Sandor Solyom
Istvan Tarnawa
Ferenc Andrasi
Istvan Ling
Tamas Hamori
Katalin Horvath
Original Assignee
Ivax Drug Res Inst Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Drug Res Inst Ltd filed Critical Ivax Drug Res Inst Ltd
Application granted granted Critical
Publication of DK1001956T3 publication Critical patent/DK1001956T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98936578T 1997-07-31 1998-07-27 2,3-Benzodiazepinderivater DK1001956T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701325A HUP9701325A1 (hu) 1997-07-31 1997-07-31 Új 2,3-benzodiazepin-származékok
PCT/HU1998/000071 WO1999006408A1 (en) 1997-07-31 1998-07-27 New 2,3-benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
DK1001956T3 true DK1001956T3 (da) 2003-08-18

Family

ID=89995445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936578T DK1001956T3 (da) 1997-07-31 1998-07-27 2,3-Benzodiazepinderivater

Country Status (13)

Country Link
US (1) US6482819B1 (ko)
EP (1) EP1001956B1 (ko)
JP (1) JP2001512124A (ko)
KR (2) KR100521959B1 (ko)
AT (1) ATE239729T1 (ko)
AU (1) AU741162B2 (ko)
CA (1) CA2296586C (ko)
DE (1) DE69814401T2 (ko)
DK (1) DK1001956T3 (ko)
ES (1) ES2202879T3 (ko)
HU (1) HUP9701325A1 (ko)
PT (1) PT1001956E (ko)
WO (1) WO1999006408A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041671C1 (de) * 2000-08-10 2002-06-13 Schering Ag Verfahren zur Herstellung von Imidazo[1,2-c][2,3]benzodiazepinen sowie Phenylessigsäureester und Oxazol-Derivate als Zwischenprodukte bei deren Herstellung
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN112321401B (zh) * 2020-11-10 2023-04-28 西安石油大学 一种催化氧化异色满制备2-羟乙基苯基酮的方法
EP4403185A1 (en) 2021-09-15 2024-07-24 University of The Ryukyus Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
WO2023042887A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
DE4428835A1 (de) 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
CA2198751C (en) * 1994-08-31 2006-07-11 Benjamin Alan Anderson Dihydro-2,3-benzodiazepine derivatives
DE19604919A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US6482819B1 (en) 2002-11-19
HUP9701325A1 (hu) 2000-08-28
HU9701325D0 (en) 1997-09-29
ES2202879T3 (es) 2004-04-01
AU741162B2 (en) 2001-11-22
KR20010022294A (ko) 2001-03-15
EP1001956B1 (en) 2003-05-07
WO1999006408A1 (en) 1999-02-11
EP1001956A1 (en) 2000-05-24
DE69814401T2 (de) 2004-02-26
CA2296586A1 (en) 1999-02-11
KR20010022287A (ko) 2001-03-15
ATE239729T1 (de) 2003-05-15
PT1001956E (pt) 2003-09-30
CA2296586C (en) 2007-04-03
JP2001512124A (ja) 2001-08-21
AU8554098A (en) 1999-02-22
DE69814401D1 (de) 2003-06-12
KR100521959B1 (ko) 2005-10-14

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
MY133392A (en) Novel substituted pyrazole derivatives
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
DK1056704T3 (da) Antitumormidler
BG104983A (en) Aryl fused azapolycyclic compounds
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
ATE239729T1 (de) 2,3-benzodiazepin-derivate
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
GEP19991780B (en) Use of Pyrrolidine Derivatives for Treating Alcoholism
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
DE69614508D1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial